Last updated: November 1, 2026
PerioChip is a localized periodontal drug-device product containing 2.5 mg chlorhexidine gluconate in a biodegradable dental insert. It is used as an adjunct to scaling and root planing for adult periodontitis. The product has a narrow commercial market, limited public financial disclosure, and a mature regulatory profile. Its economics depend more on dental-practice adoption, procedure volume, reimbursement, and manufacturing continuity than on broad pharmaceutical market expansion.
Public sources do not disclose PerioChip-specific revenue, operating profit, unit volume, or valuation. The available evidence supports a mature, niche-product assessment rather than a high-growth pharmaceutical profile.
What is PerioChip and how does it work?
PerioChip is inserted into periodontal pockets after mechanical cleaning. The insert releases chlorhexidine locally over approximately seven to 10 days, reducing bacterial load without requiring systemic antibiotic exposure.
| Product attribute |
Publicly reported information |
| Brand |
PerioChip |
| Active ingredient |
Chlorhexidine gluconate |
| Dose |
2.5 mg per periodontal insert |
| Dosage form |
Biodegradable dental insert |
| Administration |
Placement in periodontal pockets by a dental professional |
| Primary use |
Adjunctive treatment of adult periodontitis |
| Market category |
Prescription dental product |
| Delivery model |
In-office periodontal procedure |
| Systemic exposure |
Intended to be predominantly local |
| Manufacturer history |
Associated with Dexcel Pharma and predecessor commercialization arrangements |
The product differs from chlorhexidine mouth rinses because it delivers the active ingredient directly into periodontal pockets. It also differs from systemic antibiotics because treatment is localized and procedure-based.
Clinical studies have evaluated PerioChip as an adjunct to scaling and root planing. The commercial value proposition is a localized antimicrobial treatment that can be applied during a periodontal visit without relying on patient adherence to a multi-day oral regimen.
What is the FDA regulatory status of PerioChip?
PerioChip was approved in the United States through a New Drug Application, commonly identified in FDA records as NDA 020971. FDA labeling describes the product as a chlorhexidine gluconate dental insert for use with scaling and root planing in adult periodontitis.[1]
The product is not a biologic and does not create a biosimilar pathway. A competing product would generally require an abbreviated new drug application only if it could satisfy applicable pharmaceutical equivalence, bioequivalence, quality, and labeling requirements. Because PerioChip is a locally administered biodegradable insert, demonstrating equivalence may be more complex than for a conventional oral tablet.
What is the Orange Book status of PerioChip?
FDA Orange Book records are the relevant source for listed patents, therapeutic-equivalence ratings, and current marketing status.[2] PerioChip’s regulatory history is mature, and the core approval dates from the late 1990s. The commercial significance of any original patent protection is therefore limited because standard U.S. patent terms for patents filed after June 8, 1995 generally run 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment and other statutory provisions.[3]
Public commercial information does not establish a currently enforceable, product-blocking Orange Book patent covering the original PerioChip product. Any freedom-to-operate assessment must review the current Orange Book listing, issued patent claims, terminal disclaimers, and later patents covering formulations, manufacturing, or delivery characteristics.
When does PerioChip lose exclusivity?
PerioChip’s principal market exclusivity period has already matured past the normal life of its original regulatory and patent protection.
| Exclusivity category |
PerioChip assessment |
| FDA approval |
Established in the late 1990s |
| New chemical entity exclusivity |
Not expected to remain relevant |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
No public indication of a commercially material current period |
| Core patent term |
Expected to have expired or be near expiration depending on the specific patent family |
| Formulation or process patents |
Must be reviewed patent-by-patent |
| Current commercial moat |
Brand recognition, dental workflow, manufacturing know-how, and limited market size |
The practical distinction is between legal exclusivity and commercial defensibility. Even after core patents expire, a niche dental insert may retain sales because dentists are familiar with the product, alternatives may lack identical delivery characteristics, and the market may be too small to attract multiple generic manufacturers.
What patents protect PerioChip?
The original product likely relied on patents covering a biodegradable periodontal insert, chlorhexidine delivery, polymer composition, and controlled local release. The commercially relevant questions are whether those patents remain enforceable and whether any later patents cover the marketed product.
A complete patent analysis would normally include:
- U.S. composition-of-matter patents;
- biodegradable polymer and matrix patents;
- controlled-release formulation claims;
- periodontal-pocket administration claims;
- manufacturing-process patents;
- packaging and stability claims;
- continuation and divisional applications;
- foreign patent-family members;
- Orange Book-listed patents;
- litigation history involving validity, infringement, or patent-term calculations.
No publicly disclosed patent portfolio supports treating PerioChip as a strongly protected, newly patented product. Its primary commercial protection is more likely operational than exclusivity-driven.
What formulations are protected by PerioChip-related patents?
The key technical protection areas are the insert’s polymer matrix, chlorhexidine loading, release profile, mechanical handling properties, and biodegradation behavior. A competitor could avoid direct infringement by changing polymer composition, insert geometry, manufacturing conditions, drug loading, or release kinetics, provided the alternative remained therapeutically acceptable.
Formulation design also creates regulatory barriers. A product that is chemically different but clinically similar may not qualify for a simple generic pathway. A company may instead need a new drug application supported by local tolerability, pharmacokinetic or pharmacodynamic evidence, manufacturing validation, and comparative clinical data.
How strong is the PerioChip patent estate?
The patent estate appears commercially moderate to weak for the original product, based on product age and the absence of widely reported current patent litigation or late-life exclusivity events.
| Patent-strength factor |
Assessment |
| Age of core product |
Mature |
| Likely status of early patents |
Expired or close to expiry |
| Product-specific delivery technology |
Can create design-around barriers |
| Orange Book leverage |
Requires current record verification |
| Litigation visibility |
No major, widely reported current dispute identified |
| Generic substitution risk |
Moderate if a technically equivalent insert is developed |
| Commercial switching risk |
Lower than legal patent risk because dental products rely on clinician familiarity |
The product’s residual defensibility is strongest where manufacturing consistency, polymer processing, stability, and dental-office usability matter. Those barriers may deter small competitors but generally do not create the same protection as an unexpired composition patent.
What generic entry risks exist for PerioChip?
Generic entry is possible but not necessarily straightforward. A competing manufacturer would need to address four risks.
First, the product is a local insert rather than a conventional oral dosage form. Bioequivalence may require more than comparative blood-level testing because systemic exposure may not adequately reflect local periodontal performance.
Second, the biodegradable matrix must release chlorhexidine at a clinically useful rate while maintaining physical integrity during placement.
Third, the product is used during a dental procedure. A generic manufacturer must persuade dentists that insertion, handling, retention, and patient tolerability are equivalent.
Fourth, the addressable market may not justify development costs. A limited periodontal-product market can produce weak returns even when legal barriers are low.
What generic launch scenarios are most likely?
| Scenario |
Commercial outcome |
| No competing insert |
PerioChip retains niche pricing and clinician familiarity |
| One approved competitor |
Price pressure begins, especially in institutional and dental-group purchasing |
| Multiple competitors |
Product becomes more commodity-like; manufacturing cost becomes decisive |
| Alternative local antimicrobial |
Substitution occurs without direct generic equivalence |
| Generic oral or rinse-based therapy |
Competes on cost but does not replicate the in-pocket delivery model |
The most credible threat is not necessarily an AB-rated generic. It is substitution by other local periodontal antimicrobials, dental procedures, antimicrobial rinses, or improved mechanical therapy.
What is PerioChip’s market size and revenue exposure?
PerioChip operates in a narrow segment of the periodontal-treatment market. Its sales are tied to the number of treated periodontal pockets and the frequency with which dentists use adjunctive local antimicrobials.
Public sources do not provide audited PerioChip revenue or unit sales. The product’s financial exposure should therefore be modeled using operating assumptions rather than reported brand financials.
A simplified revenue framework is:
Revenue = treated patients × inserts per patient × price per insert × channel realization
Important variables include:
- adult periodontitis prevalence;
- referral volume to periodontists;
- scaling and root-planing procedures;
- reimbursement and patient out-of-pocket costs;
- number of sites treated per visit;
- repeat treatment frequency;
- dental-practice purchasing behavior;
- distributor discounts;
- product wastage and inventory turnover.
The product is unlikely to have material exposure to hospital formularies or primary-care prescribing. Its revenue base is concentrated in periodontal specialists, general dentists who perform advanced periodontal procedures, dental clinics, and distributors.
What drives PerioChip’s financial trajectory?
PerioChip’s financial trajectory is likely mature to declining unless the sponsor expands adoption, secures new geographic distribution, or increases use in periodontal treatment protocols.
Volume drivers
Volume can rise if:
- more patients receive periodontal maintenance;
- dentists adopt adjunctive pocket treatment;
- clinical guidelines support local antimicrobial use;
- dental insurance improves reimbursement;
- specialist practices increase procedural throughput;
- the sponsor expands education and distribution.
Pricing drivers
Pricing power depends on clinical differentiation and switching costs. The product has some ability to command a premium over basic chlorhexidine rinses because it is administered locally and professionally. That premium is constrained by the availability of mechanical treatment, lower-cost topical products, and patient sensitivity to dental out-of-pocket expenses.
Cost drivers
Manufacturing costs include chlorhexidine raw material, biodegradable polymer components, controlled-release processing, sterile or controlled packaging requirements, quality testing, and regulatory compliance. For a low-volume product, fixed manufacturing and quality costs can be significant per unit.
The financial model is therefore sensitive to plant utilization. A relatively small decline in volume can pressure margins if production, validation, and regulatory costs remain fixed.
Which companies are challenging PerioChip?
No major, publicly documented Paragraph IV campaign against PerioChip has emerged as a defining feature of the product’s commercial history. The competitive set is broader than direct generic inserts and includes:
- manufacturers of local antimicrobial periodontal products;
- developers of sustained-release dental delivery systems;
- suppliers of chlorhexidine rinses and gels;
- providers of systemic periodontal antibiotics;
- dental companies selling mechanical treatment systems;
- emerging products using alternative antimicrobials or drug-device combinations.
The absence of a visible Paragraph IV dispute does not establish that no challenge exists. It indicates that PerioChip has not generated a widely reported challenge comparable to high-revenue pharmaceutical products.
What patent litigation and settlement agreements affect PerioChip?
No major current patent litigation or settlement agreement is widely associated with PerioChip in public pharmaceutical reporting. The absence of litigation is commercially consistent with a mature product whose sales are concentrated in a small dental market.
A potential entrant would still need to evaluate:
- Orange Book certifications;
- patent-infringement risk;
- ownership and assignment records;
- manufacturing know-how;
- trade-secret exposure;
- regulatory exclusivity;
- product-liability history;
- distributor and license agreements.
Publicly disclosed licensing economics for PerioChip are not available. Historical commercialization arrangements involving product ownership, manufacturing, or geographic distribution should not be treated as evidence of current exclusivity without reviewing the operative agreements.
How does PerioChip compare with chlorhexidine rinses and systemic antibiotics?
| Attribute |
PerioChip |
Chlorhexidine rinse |
Systemic antibiotic |
| Delivery |
Periodontal pocket insert |
Whole-mouth rinse |
Systemic oral administration |
| Administration |
Dental professional |
Patient |
Patient or clinician-directed |
| Adherence dependence |
Low after placement |
High |
Moderate |
| Local concentration |
High at treatment site |
More diffuse |
Variable |
| Procedure integration |
High |
Low |
Low to moderate |
| Cost per treatment |
Generally higher than rinse |
Lower |
Variable |
| Antimicrobial exposure |
Localized |
Local oral exposure |
Systemic |
| Generic substitution |
Technically complex |
More straightforward |
Established |
| Primary commercial barrier |
Workflow and formulation |
Brand and distribution |
Clinical positioning and resistance concerns |
PerioChip’s differentiation is delivery. Its weakness is that it requires a dental visit and may add cost to a procedure that clinicians can perform without the insert.
What geographic markets matter for PerioChip?
The United States is strategically important because of its large dental market and FDA-approved product history. European and other international markets depend on country-specific registrations, reimbursement, distributor arrangements, and local product classifications.
The product’s geographic expansion is limited by:
- country-level registration requirements;
- dental reimbursement practices;
- local procurement structures;
- language-specific labeling;
- distributor economics;
- manufacturing and supply-chain reliability;
- differing periodontal-treatment guidelines.
A mature dental product can remain commercially viable in selected countries even when it has limited global scale. Local distributor access can be more important than broad consumer awareness.
Key Takeaways
- PerioChip is a mature chlorhexidine gluconate periodontal insert, not a high-growth pharmaceutical asset.
- Its core commercial value comes from localized delivery during periodontal procedures.
- Public sources do not disclose product-specific revenue, profit, unit volume, or transaction valuation.
- The original exclusivity period is no longer the primary commercial barrier.
- Patent strength likely depends on later formulation, manufacturing, and delivery claims rather than the original product concept.
- Generic entry is technically possible but may be constrained by local-delivery bioequivalence, small market size, and manufacturing complexity.
- Competitive risk includes alternative periodontal products and procedures, not only direct generic inserts.
- Financial performance is likely driven by dental-practice adoption, reimbursement, pricing, and distributor coverage.
- No major current Paragraph IV challenge, patent litigation campaign, or settlement agreement is widely reported.
- The asset is best characterized as a defensible niche product with mature or declining baseline economics.
FAQs
Is PerioChip still commercially available?
Availability varies by country and distributor. Regulatory approval does not guarantee continuous commercial supply in every market.
Is PerioChip an antibiotic?
No. PerioChip contains chlorhexidine gluconate, an antimicrobial antiseptic, rather than a conventional systemic antibiotic.
Can PerioChip be purchased over the counter?
No. It is intended for professional dental use and is generally supplied through prescription or dental-practice channels.
Does PerioChip have biosimilar competition?
No. PerioChip is a small-molecule drug insert and is not subject to the biosimilar approval pathway.
Is PerioChip a high-value licensing target?
Usually not on revenue scale alone. Its value would depend on acquisition price, geographic rights, manufacturing capability, distributor access, and the buyer’s ability to expand dental adoption.
References
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term provisions. https://www.uspto.gov/patents/laws
- Electronic Medicines Compendium. (n.d.). PerioChip 2.5 mg dental insert: Summary of product characteristics. https://www.medicines.org.uk/
- Goodson, J. M., Cugini, M. A., Kent, R., Armitage, G. C., Cobb, C. M., Fine, D., Fritz, M. E., Imoberdorf, M., Killoy, W., Kowalski, C. J., et al. (1998). Multicenter evaluation of tetracycline fiber therapy: II. Clinical response. Journal of Periodontal Research, 33(6), 354-362.
